Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase III Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics announced commencement of dosing in HOPE-3, a Phase III clinical trial investigating CAP-1002, a cell therapy for treating late-stage Duchenne muscular dystrophy